Methods of treating patients at risk for renal injury and renal failure
US11435364B2 · kind B2 · utility
3Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 2019 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | May 24, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.